AYTU BIOPHARMA, INC — Net Income by Fiscal Year
20 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/bc3db31d-fa98-4c0b-aaca-c11530673175/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-13.6M | 2024-07-01 – 2025-06-30 | evidence 0001437749-25-029723 |
| FY 2024 | $-15.8M | 2023-07-01 – 2024-06-30 | evidence 0001437749-24-030062 |
| FY 2023 | $-17.1M | 2022-07-01 – 2023-06-30 | evidence 0001558370-23-016393 |
| FY 2022 | $-108.8M | 2021-07-01 – 2022-06-30 | evidence 0001558370-23-016393 |
| FY 2021 | $-58.3M | 2020-07-01 – 2021-06-30 | evidence 0001558370-21-012825 |
| FY 2020 | $-13.6M | 2019-07-01 – 2020-06-30 | evidence 0001558370-21-012825 |
| FY 2019 | $-27.1M | 2018-07-01 – 2019-06-30 | evidence 0001654954-19-011147 |
| FY 2018 | $-10.2M | 2017-07-01 – 2018-06-30 | evidence 0001213900-18-012209 |
| FY 2017 | $-22.5M | 2016-07-01 – 2017-06-30 | evidence 0001144204-17-046061 |
| FY 2016 | $-28.2M | 2015-07-01 – 2016-06-30 | evidence 0001144204-16-122393 |
| FY 2015 | $-7.7M | 2014-07-01 – 2015-06-30 | evidence 0001193125-15-333046 |
| FY 2014 | $-61.7k | 2013-09-01 – 2014-08-31 | evidence 0001079974-15-000022 |
| FY 2013 | $-618.7k | 2005-03-01 – 2014-05-31 | evidence 0001079974-14-000542 |
| FY 2012 | $-557.7k | 2005-03-01 – 2013-05-31 | evidence 0001079974-13-000336 |
| FY 2011 | $-492.9k | 2005-03-01 – 2012-05-31 | evidence 0001079974-12-000288 |
| FY 2010 | $-60.3k | 2009-09-01 – 2010-08-31 | evidence 0001354488-11-005179 |
| FY 2009 | $-58.9k | 2008-09-01 – 2009-08-31 | evidence 0001354488-11-005179 |
| FY 2008 | $-57.2k | 2007-09-01 – 2008-08-31 | evidence 0001354488-11-005179 |
| FY 2007 | $-49.0k | 2006-09-01 – 2007-08-31 | evidence 0001354488-11-005179 |
| FY 2006 | $-70.4k | 2005-09-01 – 2006-08-31 | evidence 0001354488-11-005179 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
AYTU BIOPHARMA, INC — all facts · Revenue · Operating Income